logo
Plus   Neg
Share
Email

Amarin: Cardiovascular Outcomes Study Of Vascepa Capsules Met Primary Endpoint

Amarin Corporation plc (AMRN) announced Monday that the Vascepa cardiovascular or CV outcomes trial, REDUCE-IT, met its primary endpoint.

In pre-market activity on Nasdaq, Amarin shares were surging around 163.6 percent to trade at $7.88.

The company noted that REDUCE-IT, a global study of 8,179 statin-treated adults with elevated CV risk, demonstrated an approximately 25% relative risk reduction, to a high degree of statistical significance, in major adverse CV events or MACE in the intent-to-treat patient population with use of Vascepa 4 grams/day as compared to placebo.

This result was supported by robust demonstrations of efficacy across multiple secondary endpoints.

Vascepa was well tolerated with a safety profile consistent with clinical experience associated with omega-3 fatty acids and current FDA-approved labeling. The proportions of patients experiencing adverse events and serious adverse events in REDUCE-IT were similar between the active and placebo treatment groups. Median follow-up time in REDUCE-IT was 4.9 years.

Amarin said it is eager to share REDUCE-IT data in greater detail with both the medical community and regulatory authorities. REDUCE-IT results have been accepted for presentation at the 2018 Scientific Sessions of the American Heart Association (AHA) on November 10, 2018 in Chicago, Illinois.

The presentation is classified as late breaking clinical trial results, which was granted based on the ability of REDUCE-IT to address a critical question in cardiovascular prevention.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said that the current state of the COVID-19 pandemic in the U.S. is "really not good." The U.S. is the country worst-affected by the coronavirus and has recently seen a surge in coronavirus infections as lockdown restrictions are eased. Granules Pharmaceuticals, Inc. recalled twelve (12) lots of type 2 diabetes medication Metformin hydrochloride Extended-Release, in the form of oral film-coated tablets, for the potential presence of nitrosamine impurity, N-Nitrosodimethylamine (NDMA), above levels of the Acceptable Daily Intake Limit (ADI), the U.S. Food and Drug Administration or FDA said in a statement. Palantir Technologies Inc., the Silicon Valley big data analytics company that has handled U.S. government's certain sensitive projects, said it has confidentially filed documents with the Securities and Exchange Commission to go public. In a statement, the company said the proposed public listing of its Class A common stock is expected to take place after the SEC completes its review process.
Follow RTT